AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03573154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: administration of the liquid 1 and then the liquid 2
Description: The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
Study NCT03573154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: administration of the liquid 2 and then the liquid 1
Description: The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
Study NCT00620386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils
Description: Endotracheal intubation using Bonfils Intubating Fiberscope
Study NCT00620386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Endotracheal intubation using Macintosh laryngoscopy
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg Suspension
Description: Single oral dose of 150 mg of PF-02413873 suspension
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Suspension
Description: Single oral dose of 30 mg of PF-02413873 suspension
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Suspension
Description: Single oral dose of 400 mg of PF-02413873 suspension
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Suspension
Description: Single oral dose of 5 mg of PF-02413873 suspension
Study NCT04560049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: application of silver nitrate to sinus tract
Study NCT04560049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenol
Description: phenolisation of sinus tract
Study NCT02500953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg Suspension
Description: Single oral dose of 750 mg of PF-02413873 suspension
Study NCT03736889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab (BGB-A317)
Description: Anti-PD-1 Antibody
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg Tablet
Description: Single oral dose of 150 mg of PF-02413873 tablets
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Tablet
Description: Single oral dose of 30 mg of PF-02413873 tablets
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Tablet
Description: Single oral dose of 400 mg of PF-02413873 tablets
Study NCT03188887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticotherapy
Description: 3 IV pulses steroids followed by oral steroids for 4 months
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Tablet
Description: Single oral dose of 5 mg of PF-02413873 tablets
Study NCT03188887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)
Description: treatment with Renin angiotensin system (RAS) blockade or SGLT2i
Study NCT03188887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)
Description: treatment with Renin angiotensin system (RAS) blockade or SGLT2i
Study NCT02004834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: Comparing: 0,5% levobupivacaine with 2% lidocaine
Study NCT01456325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
Study NCT01456325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
Study NCT04173000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software with medication continuity tools
Description: Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
Study NCT01456325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMab)
Description: Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
Study NCT01456325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Study NCT01277939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Description: Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
Study NCT01277939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
Study NCT04173000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software without medication continuity tools
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.
Study NCT03471637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Description: Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]
Study NCT00455104 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational, voluntary registry.
Study NCT00286832 — intervention group
Intervention type: PROCEDURE
Intervention: PET scan
Description: One extra PET scan after 1 cycle of treatment.
Study NCT04070300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise
Description: Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
Study NCT01801787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: active vs. sham tDCS left hemisphere
Study NCT01838707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine HCL @ 4-5 ml/h
Study NCT01838707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h
Study NCT01838707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
Study NCT02830893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARA
Description: Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
Study NCT02830893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
Study NCT01698567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antithrombin III
Description: ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
Study NCT01698567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
Study NCT01801787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: active vs. sham tDCS left hemisphere
Study NCT00908960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT03509038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploratory pathophysiology Study
Description: Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
Study NCT01342718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal extract granule and probiotics
Description: The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)
Study NCT01342718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Herbal extract granule and placebo probiotics
Description: The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Study NCT01342718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule and probiotics
Description: The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)
Study NCT01342718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo herbal extract granule and placebo probiotics
Description: The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S).
Study NCT02992496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1mg/kg, 6 applications over 2 weeks
Study NCT02992496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: 0.03mg/kg, 6 applications over 2 weeks
Study NCT03243838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
Study NCT00857571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg Tablet
Description: Single oral dose of 750 mg of PF-02413873 tablets
Study NCT03916718 — intervention group
Intervention type: BEHAVIORAL
Intervention: Care EcoSystem
Description: This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
Study NCT01837628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Gel
Study NCT01837628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paraffin Oil
Study NCT02861950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block with ropivacaine
Description: Patients in this arm will receive a caudal block with ropivacaine
Study NCT02861950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: penile nerve block with bupivacaine
Description: Patients in this arm will receive a penile block with bupivacaine
Study NCT02815748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SP2086
Description: SP2086 was taken only one time at 100mg dose in health volunteers
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (LD formulation 1)
Description: Intramuscular injection
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection
Study NCT04443556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
Study NCT04443556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV PCA
Description: An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
Study NCT04443556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA
Description: An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
Study NCT03650972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Samarin
Description: Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
Study NCT03168464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Study NCT03168464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Study NCT03168464 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
Study NCT00951431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 20mg daily for 8 weeks
Study NCT00951431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in the form of study drug
Study NCT03172936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIW815
Description: MIW 815 (ADU-S100) is a STING agonist
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular injection
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13™
Description: Intramuscular injection
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection
Study NCT01815294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB
Description: Cycle 1 = Treatment A, Cycle 2 = Treatment B
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hib
Description: Intramuscular injection
Study NCT01815294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
Description: Cycle 1 = Treatment B, Cycle 2 = Treatment A
Study NCT01262872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Orally
Study NCT03462771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 4g of fish oil daily for 14 weeks
Study NCT03462771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: 4g of sunflower oil daily for 14 weeks
Study NCT03172936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is an anti-PD-1 antibody
Study NCT04421534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: adding lactoferrin to standard of care treatment regimens
Study NCT04421534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: adding lactoferrin to standard of care treatment regimens
Study NCT06102278 — intervention group
Intervention type: OTHER
Intervention: Peritoneal Metastasis
Description: Patients experiencing postoperative peritoneal metastasis
Study NCT02489799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance care planning video
Description: This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
Study NCT02489799 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control video
Description: This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
Study NCT00589745 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal potential difference measurement
Description: Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.